Skip to content
DataLookout
Menu

NCT07916883

PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)

StatusRecruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Site details revised at 2 of 2 sites
  2. Minor Interventions modified
    • Secondary endpoints: details revised at 3 of 7 entries
    • Study description expanded, about 3 words
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Comparison of 64Cu-NODAGA-CANF PET SUV (Standardized Uptake Value) between the atherosclerosis of the target diseased carotid artery and the non-diseased contralateral carotid artery or non-diseased vertebral artery
Timeframe: Up to 4 hours post-injection of 64Cu-NODAGA-CANF

Secondary (7)

Correlation of 64Cu-NODAGA-CANF PET uptake to American Heart Association (AHA) stage of atherosclerotic plaque as determined by MRI
Correlation of 64Cu-NODAGA-CANF PET uptake to absence or presence of atherosclerosis as determined by MRI
Correlation of 64Cu-NODAGA-CANF PET uptake to absence or presence of lipid core as determined by MRI
Correlation of 64Cu-NODAGA-CANF PET uptake to absence or presence of hemorrhage as determined by MRI
Correlation of 64Cu-NODAGA-CANF PET uptake to outcomes
Show 2 moreShow less
Correlation of 64Cu-NODAGA-CANF PET uptake to American Heart Association (AHA) stage of atherosclerotic plaque as determined by histology on ex vivo tissue specimens for patients undergoing CEA surgery
Correlation of 64Cu-NODAGA-CANF PET uptake to expression of targeted receptor, NPR-C, by immunohistochemistry on ex vivo tissue specimens for patients undergoing CEA surgery

Arms and interventions

Patients treated with Optimal Medical Therapy (OMT) alone

Asymptomatic carotid artery stenosis (ACAS) patients with known carotid artery atherosclerosis by ultrasound/Doppler or other carotid imaging with ≥ 60% diameter stenosis who are clinically referred for OMT alone.

Patients treated with OMT and carotid endartarectomy (CEA)

Asymptomatic carotid artery stenosis (ACAS) patients with known carotid artery atherosclerosis by ultrasound/Doppler or other carotid imaging with ≥ 60% diameter stenosis who are clinically referred for OMT and CEA.

Drugs: 64Cu-NODAGA-CANF, Optimal Medical Therapy (OMT)

Procedures: Carotid Endarterectomy (CEA) surgery

Sites

2 sites in 1 country